OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management
Enríque Alvarez, Erin E. Longbrake, Kottil Rammohan, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 79, pp. 105009-105009
Open Access | Times Cited: 22
Enríque Alvarez, Erin E. Longbrake, Kottil Rammohan, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 79, pp. 105009-105009
Open Access | Times Cited: 22
Showing 22 citing articles:
Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability
Alise Carlson, Moein Amin, Jeffrey A. Cohen
Drugs (2024) Vol. 84, Iss. 3, pp. 285-304
Open Access | Times Cited: 18
Alise Carlson, Moein Amin, Jeffrey A. Cohen
Drugs (2024) Vol. 84, Iss. 3, pp. 285-304
Open Access | Times Cited: 18
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients
Anas Elgenidy, Nagham Nader Abdelhalim, Mohammed Al-mahdi Al-kurdi, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 9
Anas Elgenidy, Nagham Nader Abdelhalim, Mohammed Al-mahdi Al-kurdi, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 9
Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study
André Aires Fernandes, Ana Lídia Neves, Daniela Ferro, et al.
Frontiers in Neurology (2025) Vol. 15
Open Access | Times Cited: 1
André Aires Fernandes, Ana Lídia Neves, Daniela Ferro, et al.
Frontiers in Neurology (2025) Vol. 15
Open Access | Times Cited: 1
Development and Validation of a Scoring System for Predicting Disease Activity in Treatment-Naïve Patients with Relapsing-Remitting Multiple Sclerosis
Magd Zakaria, Nevin Shalaby, Farouk Talaat, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 94, pp. 106278-106278
Closed Access | Times Cited: 1
Magd Zakaria, Nevin Shalaby, Farouk Talaat, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 94, pp. 106278-106278
Closed Access | Times Cited: 1
Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience
Martina Nasello, Valeria Zancan, Virginia Rinaldi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5353-5353
Open Access | Times Cited: 4
Martina Nasello, Valeria Zancan, Virginia Rinaldi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5353-5353
Open Access | Times Cited: 4
Extended-interval dosing of rituximab/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosis
Camille Rigollet, Sean A. Freeman, Marine Perriguey, et al.
Neurotherapeutics (2025), pp. e00554-e00554
Open Access
Camille Rigollet, Sean A. Freeman, Marine Perriguey, et al.
Neurotherapeutics (2025), pp. e00554-e00554
Open Access
Long-Term Evaluation of Effectiveness and Immunological Implications of Ocrelizumab in a Real-World Cohort
Tommaso Guerra, Francesca Caputo, Antonella Bianco, et al.
Drugs - Real World Outcomes (2025)
Open Access
Tommaso Guerra, Francesca Caputo, Antonella Bianco, et al.
Drugs - Real World Outcomes (2025)
Open Access
Choosing initial MS therapy; personal, disease, and medication factors
Bruce A. Cohen
Neurotherapeutics (2025), pp. e00582-e00582
Open Access
Bruce A. Cohen
Neurotherapeutics (2025), pp. e00582-e00582
Open Access
The Histologic Spectrum of Rituximab-Associated Common Variable Immunodeficiency-Like Enteropathy
Pari Jafari, David Hakimian, Maria Westerhoff, et al.
Modern Pathology (2025), pp. 100770-100770
Closed Access
Pari Jafari, David Hakimian, Maria Westerhoff, et al.
Modern Pathology (2025), pp. 100770-100770
Closed Access
Selective IgM Hypogammaglobulinemia and Multiple Sclerosis Treated with Natalizumab and Ofatumumab: A Case Report
Francesco Crescenzo, M. Turazzini, Francesca Rossi
Journal of Personalized Medicine (2025) Vol. 15, Iss. 4, pp. 155-155
Open Access
Francesco Crescenzo, M. Turazzini, Francesca Rossi
Journal of Personalized Medicine (2025) Vol. 15, Iss. 4, pp. 155-155
Open Access
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells
Federica Galota, Simone Marcheselli, Sara De Biasi, et al.
Cells (2025) Vol. 14, Iss. 8, pp. 606-606
Open Access
Federica Galota, Simone Marcheselli, Sara De Biasi, et al.
Cells (2025) Vol. 14, Iss. 8, pp. 606-606
Open Access
Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study
Paolo A. Muraro, Antonio Zito, Alessio Signori, et al.
Annals of Neurology (2025)
Open Access
Paolo A. Muraro, Antonio Zito, Alessio Signori, et al.
Annals of Neurology (2025)
Open Access
Perspectives on the de-escalation of anti-CD20 monoclonal antibodies in patients with multiple sclerosis
Abdorreza Naser Moghadasi
Expert Opinion on Biological Therapy (2025)
Closed Access
Abdorreza Naser Moghadasi
Expert Opinion on Biological Therapy (2025)
Closed Access
Clinical opinions and case studies on understanding and managing hypogammaglobulinaemia in multiple sclerosis: United Kingdom perspective
Sharmilee Gnanapavan, Angray S. Kang, David Baker, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 96, pp. 106353-106353
Open Access
Sharmilee Gnanapavan, Angray S. Kang, David Baker, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 96, pp. 106353-106353
Open Access
IgG Biomarkers in Multiple Sclerosis: Deciphering Their Puzzling Protein A Connection
Leonard Apeltsin, Xiaoli Yu
Biomolecules (2025) Vol. 15, Iss. 3, pp. 369-369
Open Access
Leonard Apeltsin, Xiaoli Yu
Biomolecules (2025) Vol. 15, Iss. 3, pp. 369-369
Open Access
Hypogammaglobulinemia in patients with multiple sclerosis receiving disease modifying therapies: disproportionality analysis using the EudraVigilance database
Raffaella Di Napoli, Nunzia Balzano, Concetta Rafaniello, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Raffaella Di Napoli, Nunzia Balzano, Concetta Rafaniello, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study
Susanna Hallberg, Björn Evertsson, Ellen Lillvall, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 8
Open Access | Times Cited: 2
Susanna Hallberg, Björn Evertsson, Ellen Lillvall, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 8
Open Access | Times Cited: 2
Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: a multicentre study
Krzysztof Smolik, Federico Camilli, Ivan Panzera, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 93, pp. 106191-106191
Open Access | Times Cited: 2
Krzysztof Smolik, Federico Camilli, Ivan Panzera, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 93, pp. 106191-106191
Open Access | Times Cited: 2
A personalized approach for anti-CD20 therapies in multiple sclerosis
Laura Hogenboom, Zoé L. E. van Kempen, Tomáš Kalinčík, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 91, pp. 105851-105851
Closed Access | Times Cited: 1
Laura Hogenboom, Zoé L. E. van Kempen, Tomáš Kalinčík, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 91, pp. 105851-105851
Closed Access | Times Cited: 1
Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies
René Carvajal, Breogán Rodrı́guez‐Acevedo, Lorena García-Vasco, et al.
Multiple Sclerosis Journal (2024)
Closed Access | Times Cited: 1
René Carvajal, Breogán Rodrı́guez‐Acevedo, Lorena García-Vasco, et al.
Multiple Sclerosis Journal (2024)
Closed Access | Times Cited: 1
B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease
Helen C Wu, Grace Gombolay, Jennifer H. Yang, et al.
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 10, pp. 479-494
Closed Access
Helen C Wu, Grace Gombolay, Jennifer H. Yang, et al.
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 10, pp. 479-494
Closed Access
Profiling the impact of anti-human CD20 monoclonal antibodies on lymphocyte B cell subsets and their precursors in the bone marrow and in lymphoid tissues in an immunocompromised mouse engrafted with human cells
Annalisa Moregola, Fabrizia Bonacina, Giovanni Battista Vingiani, et al.
Pharmacological Research (2024) Vol. 209, pp. 107442-107442
Open Access
Annalisa Moregola, Fabrizia Bonacina, Giovanni Battista Vingiani, et al.
Pharmacological Research (2024) Vol. 209, pp. 107442-107442
Open Access
Features of the vaginal microbiota in women with relapsing-remitting multiple sclerosis
Е. И. Лузанова, М. И. Карпова, О. С. Абрамовских, et al.
Meditsinskiy sovet = Medical Council (2024), Iss. 17, pp. 58-65
Open Access
Е. И. Лузанова, М. И. Карпова, О. С. Абрамовских, et al.
Meditsinskiy sovet = Medical Council (2024), Iss. 17, pp. 58-65
Open Access
